Fig. 1: Overview of the study screening strategy.
From: A landscape of response to drug combinations in non-small cell lung cancer
A Major cancer drivers captured by the cell line collection screened. The y-axis in this figure shows the fraction of cell lines with a driver mutation. Figure also shows the percentage of KRAS mutated cell lines which also have a P53 and STK11 mutation. B Screen set-up and key characteristics. C Anchor drugs used. D Library drugs used grouped by target class. Abbreviations used – DDR DNA Damage Response, Nuc_Exp Nuclear Export, Necro Necroptosis, Lipid Lipid Synthesis, Neuro_Dev neuronal development, Histone Acet Histone Acetylation, Histone Met Histone Methylation, Prot Homeo Protein Homeostasis, Metabo Metabolism, Anabo Anabolism, Mitoc Mitochondria, N-RTK Non Receptor Tyrosine Kinase, RTK Receptor Tyrosine Kinase, Lip K Lipid Kinase, ERK_Path ERK Pathway, ST-K Serine Threonine Kinase.
